Journal List > J Stroke > v.26(3) > 1516088620

Cui, Yao, Zhang, and Chen: Early Neurological Deterioration and Time to Start Dual Antiplatelet Therapy in Patients With Acute Mild-to-Moderate Ischemic Stroke: A Pre-Specified Post Hoc Analysis of the ATAMIS Trial

Abstract

Background and Purpose

This study comprised a post hoc analysis of the Antiplatelet Therapy in Acute Mild to Moderate Ischemic Stroke (ATAMIS) trial aiming to determine whether the effect of dual antiplatelet therapy compared with that of monotherapy on preventing early neurological deterioration (END) differed according to the time from stroke onset to antiplatelet therapy (OTT).

Methods

In the ATAMIS trial, patients were divided into two subgroups: OTT from 0 to 24 hours (0–24 h group) and OTT from 24 to 48 hours (24–48 h group). We conducted multivariate regression analysis with continuous and categorical OTT to detect the effect of antiplatelet therapy. The primary outcome was END at 7 days, defined as an increase in the National Institutes of Health Stroke Scale (NIHSS) score of more than two points compared with the baseline. The safety outcomes were bleeding events and intracranial hemorrhage within 90 days.

Results

A total of 2,915 patients were included. With respect to END at 7 days, clopidogrel plus aspirin showed a lower proportion than aspirin alone across continuous OTT (4.8% vs. 6.7%; adjusted risk difference, -1.9%; 95% confidence interval [CI], -3.6% to -0.2%; P=0.03), and was lower in the 0–24 hours group (5.7% vs. 9.2%; adjusted risk difference, -3.7%; 95% CI, -5.5% to -2.0%; P<0.01), but similar in the 24–48 hours group (3.5% vs. 2.9%; adjusted risk difference, 0.6%; 95% CI, -0.8% to 2.0%; P=0.40). We identified a significant interaction between the treatment effect and time subgroup with respect to the primary outcome (P=0.03). The occurrence of bleeding events and intracranial hemorrhage was similar in the time subgroup.

Conclusion

For patients with acute mild-to-moderate ischemic stroke, clopidogrel plus aspirin was associated with a lower risk of END at 7 days than aspirin alone when it was started within 24 hours of symptom onset.

Introduction

According to current guidelines, reperfusion therapies are recommended as effective treatment strategies for patients with acute ischemic stroke [1,2]. However, a significant subset of patients cannot receive reperfusion therapies due to the strict therapeutic window as well as the lack of access to endovascular care; such patients are instead recommended to receive antiplatelet therapy. For patients with minor stroke or high-risk transient ischemic attack, the Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) [3] and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) [4] trials both found that dual antiplatelet therapy with clopidogrel and aspirin initiated within 24 hours of stroke onset significantly reduced the risk of recurrent stroke compared with aspirin alone. Recently, the Intensive Statin and Antiplatelet Therapy for Acute High-Risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial further identified that the above population with presumed atherosclerotic causes showed a greater benefit from dual antiplatelet therapy initiated within 72 hours after stroke onset than from monotherapy [5]. However, the guideline still recommends monotherapy with aspirin alone for patients with acute mild-to-moderate ischemic stroke [1], who are at high risk of early neurological deterioration (END), which is associated with poor prognosis [6].
The Antiplatelet Therapy in Acute Mild to Moderate Ischemic Stroke (ATAMIS) trial was the first randomized clinical trial with a large sample size to demonstrate that dual antiplatelet therapy with clopidogrel and aspirin could significantly reduce the risk of END at 7 days compared with aspirin alone in patients with acute mild-to-moderate ischemic stroke within 48 hours of stroke onset [7]. A prior meta-analysis also showed that dual antiplatelet therapy immediately following the index stroke was more effective than monotherapy for secondary stroke prevention [8]. However, the effect of time from stroke onset to antiplatelet therapy (OTT) on preventing END in acute mild-to-moderate stroke remains unclear.
In this context, we performed a pre-specified post hoc analysis of the ATAMIS trial to determine whether earlier dual antiplatelet therapy initiation was associated with a lower risk of END in patients with acute mild-to-moderate ischemic stroke who were not considered candidates for reperfusion therapies.

Methods

All data supporting the findings of this study are available from the corresponding author upon reasonable request.

Study design and participants

Details on the design, protocol, and statistical analysis plan of the ATAMIS trial have been previously published [7,9]. In brief, the ATAMIS trial was a multicenter, open-label, blinded-endpoint, randomized clinical trial enrolling 3,000 patients between December 20, 2016, and August 9, 2022, which aimed to assess the effect of clopidogrel plus aspirin in patients with acute mild-to-moderate ischemic stroke. The eligibility criteria included an age of 18 years or older, functioning independently before stroke (modified Rankin Scale [mRS] scores, 0–1; range, 0 [no symptoms] to 6 [death]), and diagnosis with acute mild-to-moderate ischemic stroke (baseline National Institute of Health Stroke Scale [NIHSS] scores, 4–10; range, 0–42, with higher scores indicating greater stroke severity) within 48 hours after stroke onset. The exclusion criteria were patients who met the eligibility criteria for intravenous thrombolysis or endovascular therapy and had a clear indication for anticoagulation or history of intracerebral hemorrhage. All study procedures were reviewed and approved by the Ethics Committee of the General Hospital of Northern Theater Command (Approval Number: k [2016] 6-1). Written informed consents were obtained from either the patients or their legally authorized representatives. This study was registered at ClinicalTrials.gov (NCT02869009). All patients from the modified intention-to-treat analysis set were included in the post hoc analysis. If patients were diagnosed with atrial fibrillation following randomization, they received anticoagulation therapy after antiplatelet therapy, in accordance with the national guidelines, and were included in the full analysis set based on the intention-to-treat principle. The detailed screening of patients for the analysis has been previously reported [7]. The current analysis followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline (Appendix 1).

Procedures

In the ATAMIS trial, patients were randomly assigned to receive either dual antiplatelet therapy with clopidogrel plus aspirin or monotherapy with aspirin alone. Further details of antiplatelet therapy have been described in a previous report [7]. In this post hoc analysis, according to OTT using 24 hours as a cutoff in which dual antiplatelet therapy was recommended for minor stroke by guideline [1], eligible patients were divided into two subgroups based on treatment time: 0–24 hours group (OTT <24 h) and 24–48 hours group (OTT ≥24 h). Neurological status, measured with NIHSS score, was evaluated at admission, and at 7 and 14 days after randomization. Follow-up data, including the assessment of clinical prognosis, recurrent events, and safety events, were collected 90 days after randomization.

Outcomes

In this post hoc analysis, all the outcomes paralleled the ATAMIS trial [7]. The primary outcome was occurrence of END at 7 days, defined as an increase in NIHSS of greater than 2 points compared with baseline (excluding cerebral hemorrhage) [10]. The secondary outcomes were excellent functional outcome at 90 days, defined as an mRS score of 0 to 1; a shift in the distribution of the ordinal mRS score at 90 days; a change in the NIHSS score compared with baseline at 14 days; time from randomization to occurrence of new stroke [11] within 90 days; and time from randomization to the occurrence of other vascular events (pulmonary embolism, peripheral vessel or cardiovascular event) or all-cause death within 90 days. Safety outcomes included the occurrence of any bleeding events or intracranial hemorrhage during the trial, given that these were directly associated with antiplatelet therapy. Detailed information for the outcome assessment is shown in the Supplementary Methods.

Statistical analysis

Considering the potentially imbalanced characteristics between the groups in the post hoc analysis, the primary analysis was adjusted. Continuous variables are summarized as median (interquartile range [IQR]) and categorical variables as frequencies (percentages). The baseline characteristics between groups were compared using the Mann–Whitney U test or chi-square test. For the treatment effect of outcomes, we estimated the absolute number of events, as well as the risk difference (RD), odds ratio (OR), geometric mean ratio (GMR), or hazard ratio (HR) with their 95% confidence intervals (CIs).
First, as a continuous variable, restricted cubic spline analysis with three knots at the 10th, 50th, and 90th percentile [12] was applied to explore the nonlinear association between OTT, as well as the probability of the primary outcome compared with antiplatelet therapies. The probability was calculated using binary logistic regression analysis, and the best-fit line was drawn according to probability and OTT. As a categorical variable, the primary outcome was analyzed for each subgroup.
Second, both unadjusted and adjusted generalized linear models and Cox regression analyses were performed to evaluate the effect of antiplatelet therapies on outcomes according to OTT, and in each time subgroup. The primary adjusted model included any imbalanced baseline variables (P<0.1), as well as pre-specified covariates (age, sex, history of diabetes, history of hypertension, NIHSS score at randomization, and presumed stroke cause based on the Trial of Org 10172 in Acute Stroke Treatment [TOAST] classification [13]) in the ATAMIS trial. Adjusted interactions between the OTT and the effect of antiplatelet therapy on outcomes were assessed by including imbalanced variables between time subgroups.
Third, a subgroup analysis of primary outcome was conducted according to six pre-specified factors (age [<65 yrs or ≥65 yrs], sex [female or male], history of diabetes [yes or no], history of hypertension [yes or no], NIHSS score at randomization [<7 or ≥7], and presumed stroke cause), in order to investigate the characteristics of patients benefiting from dual antiplatelet therapy in each time subgroup.
In addition, per-protocol analysis was restricted to patients who received the completed intervention, as specified in the protocol [9], while propensity score matching analysis for all outcomes was performed as a sensitivity analysis. Propensity score matching was performed to generate a new cohort with a balanced sample size between the time subgroups to control for sample-size bias. Furthermore, patients were analyzed by grouping with different OTT cutoff values, such as 12 hours or 18 hours.
Detailed information regarding the adjusted models, propensity score matching, and statistical analysis is presented in the Supplementary Methods. All analyses were exploratory, and all P values were nominal. Two-sided P values <0.05 were considered significant. All statistical analyses were performed using the SPSS software (version 26.0; IBM Corp., Armonk, NY, USA) and R software (version 4.1.0; R Foundation for Statistical Computing, Vienna, Austria).

Results

Patient characteristics

A total of 2,915 patients from the ATAMIS trial were enrolled in this post hoc analysis, including 1,757 patients in the 0–24 hours group (OTT: median [IQR], 9.0 h [5.4 to 14.5 h]) and 1,158 patients in the 24–48 hours group (OTT: median [IQR], 28.6 h [25.1 to 41.2 h]). The median (IQR) age was 66 (59–73) years, and 1,020 (35.0%) patients were women. In total, 902 patients were assigned to receive clopidogrel plus aspirin, and 855 patients were assigned to receive aspirin alone in the 0–24 hours group, whereas 600 and 558 patients were assigned to receive these treatments in the 24–48 hours group, respectively (Figure 1).
Table 1 shows the baseline characteristics of patients assigned to different antiplatelet therapies in each time subgroup. In the 0–24 hours group, a higher proportion of patients with diabetes was assigned to the clopidogrel plus aspirin group. In the 24–48 hours group, a higher proportion of patients with a history of transient ischemic attack were assigned to receive aspirin alone. We identified differences in age, sex, current smoking, current drinking, NIHSS score at admission, OTT, presumed stroke cause, and location of the responsible vessel between the 0–24 hours and 24–48 hours groups.

Association between continuous OTT and outcomes

As a natural continuous characteristic of OTT, the probability of END at 7 days was compared between the clopidogrel plus aspirin and aspirin alone groups according to OTT, which revealed that the probability decreased with a longer OTT (Figure 2A and B). Compared with aspirin alone, the analysis revealed a significantly decreased risk of END after receiving clopidogrel plus aspirin therapy (4.8% vs. 6.7%; adjusted RD, -1.9%; 95% CI, -3.6% to -0.2%; P=0.03) (Table 2). However, no significant interactions were observed (adjusted P=0.13). As such, we explored the nonlinear association between continuous OTT and the primary outcome using restricted cubic spline analysis. Although no significant nonlinear association was found (P for nonlinear=0.06) (Figure 2C and D), the odds ratio for END at 7 days, as well as that for antiplatelet therapy, decreased with longer OTT and plateaued at 48 hours.
The distribution of mRS scores at 90 days between the clopidogrel plus aspirin and aspirin alone groups is presented in Figure 3A. None of the secondary or safety outcomes were significantly different between clopidogrel plus aspirin and aspirin alone across the continuous OTT, and no significant interactions were found (Table 2).

Association between categorical OTT and outcomes

Compared with aspirin alone, the analysis revealed significantly decreased odds in END following clopidogrel plus aspirin treatment in the 0–24 hours group (5.7% vs. 9.2%; adjusted RD, -3.7%; 95% CI, -5.5% to -2.0%; P<0.01) (Table 3), while no significant difference was found in the 24–48 hours group (3.5% vs. 2.9%; adjusted RD, 0.6%; 95% CI, -0.8% to 2.0%; P=0.40) (Table 3). Significant interactions between the time subgroups and the effect of antiplatelet therapy on the primary outcome were observed (adjusted P=0.03).
The distribution of mRS scores at 90 days between the clopidogrel plus aspirin and aspirin alone groups in each time subgroup is presented in Figure 3B and C. None of the secondary or safety outcomes showed significant differences between the clopidogrel plus aspirin and aspirin alone in each time subgroup, and no significant interactions were found (Table 3).

Subgroup analysis

To explore the characteristics of patients who benefited from early dual antiplatelet therapy, we further investigated the association between OTT, as well as the effect of antiplatelet therapy on the primary outcome in relation to age, sex, history of hypertension, history of diabetes, stroke severity, and presumed stroke cause (Figure 4). In each characteristic subgroup, clopidogrel plus aspirin showed a lower risk of END at 7 days than aspirin alone in the 0–24 hours group compared with the 24–48 hours group, which was similar to the result observed in the primary analysis. Notably, significant interactions between the OTT subgroup and the effect of antiplatelet therapy on the primary outcome were identified in patients with NIHSS scores of 4 to 7 at admission (P=0.046) and an undetermined stroke etiology (P=0.01).

Sensitivity analysis

All outcomes analyzed in patients with propensity score matching and from the per-protocol analysis set were similar to those in patients from the modified intention-to-treat analysis set. As the number of OTT groups increased, the results also indicated that patients benefited more from earlier dual antiplatelet therapy. The results of the sensitivity analysis are presented in the Supplementary Results.

Discussion

In this post hoc analysis of the ATAMIS trial, we found that the risk of END 7 days after receiving antiplatelet therapy decreased as the OTT increased. Furthermore, we divided patients with acute mild-to-moderate ischemic stroke within 48 hours of symptom onset into the 0–24 hours and 24–48 hours groups according to the OTT, using 24 hours as a cutoff, with the aim of exploring the relationship between OTT and the effect of antiplatelet therapies on clinical outcomes after stroke. The results showed that, compared with patients receiving aspirin alone, the risk of END at 7 days was significantly lower in patients receiving clopidogrel plus aspirin within 24 hours of symptom onset, particularly in patients with NIHSS scores of 4 to 7 at admission, or an undetermined cause of stroke. Collectively, these findings indicated that the earlier dual antiplatelet treatment is started, the lower the risk of END in this population.
END is a common and important complication of acute ischemic stroke [14,15]. OTT is a critical characteristic of patients with ischemic stroke routinely used to select the appropriate treatment strategy in current guidelines [1], and is strongly associated with patient prognosis [16,17]. The current analysis found that the risk of END decreased with OTT, regardless of the antiplatelet strategy. This finding was similar to that reported in a prospective multicenter observational study from China [14], focusing on the worsening of patients with acute ischemic stroke receiving conventional treatment rather than reperfusion treatment, which shared a similar targeted population as the ATAMIS trial. Overall, these results may be attributed to the greater expansion and progression of existing infarct lesions in the early stage [18], which was the primary reason for ischemic END [19]. Although the risk was higher in the early stage of acute ischemic stroke, regardless of the antiplatelet treatments received (Figure 2C), a greater reduction in the risk of END after receiving dual antiplatelet therapy compared with antiplatelet monotherapy (Figure 2D) was observed, which was beneficial for functional outcome that was associated with END [15]. Collectively, these findings indicated a higher risk of END at 7 days in patients with shorter OTT than those with longer OTT, and the importance of intensive antiplatelet therapy in the early stage after stroke onset.
In the secondary analysis of the POINT trial, the benefit of dual antiplatelet therapy in acute minor ischemic stroke or transient ischemic attack with high-risk factors was greatest when dual antiplatelet therapy was initiated within 12 hours of symptom onset and persisted until 72 hours [20]. Similarly, the effect of dual antiplatelet therapy in acute mild-to-moderate ischemic stroke on preventing the occurrence of END at 7 days was also found higher within 0–24 hours of symptom onset than 24–48 hours in the current analysis. On the one hand, the higher occurrence of END in patients with shorter OTT partially contributed to the larger benefit of dual antiplatelet therapy at this stage, given that it provided the opportunity to find a significant risk difference. On the other hand, as patients with shorter OTT had a greater risk of experiencing expansion and progression of infarct lesions [18], antiplatelet therapy may play a more important role in preventing END in the early stage of stroke given stroke progression due to clot propagation [21,22]. The benefit of early antiplatelet therapy was further proven in patients receiving intravenous thrombolysis to reduce reocclusion and to improve neurological function at 7 days [23,24], which further supported our findings indicating the better benefit of early antiplatelet therapy in preventing END. Collectively, the current findings suggest that dual antiplatelet therapy should be initiated as early as possible after stroke onset to reduce the risk of END, considering its stronger antithrombotic effect than that of monotherapy.
In our subgroup analysis, we found that the interaction between the OTT and the effect of dual antiplatelet therapy was significantly associated with the NIHSS score at admission, or the presumed stroke cause. Patients with NIHSS scores of 4 to 7 at admission were found to achieve a greater benefit from early dual antiplatelet therapy than those with NIHSS scores of 8 to 10, which was in good agreement with the benefit of early dual antiplatelet therapy in patients with minor stroke observed in a previous study [20]. Interestingly, patients with an undetermined cause of stroke etiology were found to benefit significantly from early dual antiplatelet therapy. However, in the ATAMIS trial, most patients diagnosed with undetermined-cause stroke had a lower proportion of complete etiology examinations. Given the unclear and potential heterogeneous causes of stroke of undetermined cause, the association between OTT and the effect of dual antiplatelet therapy in specific stroke etiologies needs further investigation.
Overall, our study had several limitations. First, although relatively large populations of 1,757 and 1,158 patients were included in each time subgroup in this post hoc analysis, an imbalanced sample size between the treatment groups may have rendered our study underpowered. However, we conducted a propensity score matching analysis to test the robustness of the findings. Second, owing to the lack of sufficient etiological examinations, a large proportion of patients were classified as having an undetermined cause of stroke. The interactions between stroke etiology, OTT, and antiplatelet treatment efficacy in the current study should therefore be interpreted with caution. The specific causes of stroke in patients benefiting from early dual antiplatelet therapy should be explored in the future. Third, the lack of an association with functional outcomes may contradict the clinical relevance of this finding, which can be attributed to the fact that a decrease in the occurrence of END may not result in a significantly good prognosis at 90 days. Additionally, the neutral finding in preventing stroke recurrence may be due to a lack of statistical power triggered by an insufficient sample size. Fourth, the generalizability of the results must be validated in other cohorts, particularly non-Chinese populations. Fifth, as the ATAMIS trial excluded patients who received intravenous thrombolysis or endovascular therapy, our findings cannot be generalized to patients who tended to receive reperfusion treatment. Finally, we interpreted our findings with caution because of the exploratory nature of the post hoc analysis. However, these findings warrant further investigation.

Conclusions

In conclusion, this post hoc analysis of the ATAMIS trial indicates that adults with acute mild-to-moderate ischemic stroke who are not considered candidates for reperfusion treatments may benefit more from early clopidogrel plus aspirin treatment started within 24 hours of symptom onset compared with 24–48 hours of onset with respect to the prevention of END at 7 days. These findings should be confirmed in future studies.

Supplementary materials

Supplementary materials related to this article can be found online at https://doi.org/10.5853/jos.2024.02250.
Supplementary Results
Sensitivity analysis in the per-protocol analysis set
jos-2024-02250-Supplementary-Results.pdf

Notes

Funding statement

This study was supported by a grant from the Science and Technology Project Plan of Liaoning Province (2019JH2/10300027). The funders played no role in the study design, data acquisition, data analysis, data interpretation, or writing of the report.

Conflicts of interest

The authors have no financial conflicts of interest.

Author contribution

Conceptualization: HSC. Study design: HSC. Methodology: YC. Data collection: ZGY, J.Z. Investigation: ZGY. Statistical analysis: YC. Writing—original draft: YC. Writing—review & editing: YC, HSC. Funding acquisition: HSC. Approval of final manuscript: all authors.

ACKNOWLEDGMENTS

We would like to thank all the participating hospitals and clinician investigators of the ATAMIS trial.

References

1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019; 50:e344–e418.
crossref
2. Seker F, Qureshi MM, Möhlenbruch MA, Nogueira RG, Abdalkader M, Ribo M, et al. Reperfusion without functional independence in late presentation of stroke with large vessel occlusion. Stroke. 2022; 53:3594–3604.
crossref
3. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013; 369:11–19.
crossref
4. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018; 379:215–225.
crossref
5. Gao Y, Chen W, Pan Y, Jing J, Wang C, Johnston SC, et al. Dual antiplatelet treatment up to 72 hours after ischemic stroke. N Engl J Med. 2023; 389:2413–2424.
6. Wasserman JK, Perry JJ, Sivilotti ML, Sutherland J, Worster A, Émond M, et al. Computed tomography identifies patients at high risk for stroke after transient ischemic attack/nondisabling stroke: prospective, multicenter cohort study. Stroke. 2015; 46:114–119.
crossref
7. Chen HS, Cui Y, Wang XH, Ma YT, Han J, Duan YJ, et al. Clopidogrel plus aspirin vs aspirin alone in patients with acute mild to moderate stroke: the ATAMIS randomized clinical trial. JAMA Neurol. 2024; 81:450–460.
crossref
8. Kheiri B, Osman M, Abdalla A, Haykal T, Swaid B, Ahmed S, et al. Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and metaanalysis of randomized clinical trials. J Thromb Thrombolysis. 2019; 47:233–247.
crossref
9. Hou X, Li X, Wang X, Chen H. Antiplatelet therapy in acute mild-moderate ischemic stroke (ATAMIS): a parallel, randomised, open-label, multicentre, prospective study. Stroke Vasc Neurol. 2018; 3:263–267.
crossref
10. Yi X, Zhou Q, Wang C, Lin J, Chai Z. Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. J Neurol. 2018; 265:2396–2403.
11. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44:2064–2089.
crossref
12. Guo C, Song J, Li L, Yang J, Huang J, Xie D, et al. Association of procedure time with clinical and procedural outcome in patients with basilar occlusion undergoing embolectomy. Neurology. 2023; 101:e253–e266.
crossref
13. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24:35–41.
crossref
14. Liu H, Liu K, Zhang K, Zong C, Yang H, Li Y, et al. Early neurological deterioration in patients with acute ischemic stroke: a prospective multicenter cohort study. Ther Adv Neurol Disord. 2023; 16:17562864221147743.
crossref
15. Seners P, Turc G, Oppenheim C, Baron JC. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry. 2015; 86:87–94.
16. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013; 309:2480–2488.
crossref
17. Matsuo R, Yamaguchi Y, Matsushita T, Hata J, Kiyuna F, Fukuda K, et al. Association between onset-to-door time and clinical outcomes after ischemic stroke. Stroke. 2017; 48:3049–3056.
crossref
18. Seners P, Yuen N, Mlynash M, Snyder SJ, Heit JJ, Lansberg MG, et al. Quantification of penumbral volume in association with time from stroke onset in acute ischemic stroke with large vessel occlusion. JAMA Neurol. 2023; 80:523–528.
crossref
19. Simonsen CZ, Schmitz ML, Madsen MH, Mikkelsen IK, Chandra RV, Leslie-Mazwi T, et al. Early neurological deterioration after thrombolysis: clinical and imaging predictors. Int J Stroke. 2016; 11:776–782.
crossref
20. Johnston SC, Elm JJ, Easton JD, Farrant M, Barsan WG, Kim AS, et al. Time course for benefit and risk of clopidogrel and aspirin after acute transient ischemic attack and minor ischemic stroke. Circulation. 2019; 140:658–664.
21. Kim JT, Lee JS, Kim BJ, Park JM, Kang K, Lee SJ, et al. Frequency, management, and outcomes of early neurologic deterioration due to stroke progression or recurrence. J Stroke Cerebrovasc Dis. 2023; 32:106940.
crossref
22. Thanvi B, Treadwell S, Robinson T. Early neurological deterioration in acute ischaemic stroke: predictors, mechanisms and management. Postgrad Med J. 2008; 84:412–417.
crossref
23. Li W, Lin L, Zhang M, Wu Y, Liu C, Li X, et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients. Stroke. 2016; 47:2649–2651.
crossref
24. Liu J, Shi Q, Sun Y, He J, Yang B, Zhang C, et al. Efficacy of tirofiban administered at different time points after intravenous thrombolytic therapy with alteplase in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 2019; 28:1126–1132.
crossref

Figure 1.
The trial profile.
jos-2024-02250f1.tif
Figure 2.
Influence of the time from symptom onset to antiplatelet therapy on the primary outcome using nonlinear and linear models. The probability of END at 7 days, evaluated using the logistic regression model, was compared between the two antiplatelet therapies (A) and stratified by antiplatelet therapies (B). The odds ratio of END at 7 days, evaluated using the restricted cubic spline model, was compared between two antiplatelet therapies (C) and stratified by antiplatelet therapies (D). END, early neurological deterioration.
jos-2024-02250f2.tif
Figure 3.
Distribution of the modified Rankin Scale scores at 90 days. The raw distributions of scores are shown: (A) across time from symptom onset to antiplatelet therapy, (B) in the 0–24 h time subgroup, and (C) in the 24–48 h time subgroup. Scores ranged from 0 to 6: 0=no symptoms, 1=symptoms without clinically significant disability, 2=slight disability, 3=moderate disability, 4=moderately severe disability, 5=severe disability, and 6=death.
jos-2024-02250f3.tif
Figure 4.
Subgroup analysis of the effect of antiplatelet therapy on the primary outcome in time subgroups. Given that the proportions of patients with other determined causes (6 patients in the 0–24 h group and 8 patients in the 24–48 h group) and cardioembolic cause (4 patients in the 0–24 h group and 0 patients in the 24–48 h group) were small, the results in the two stroke cause subgroup are not shown in the figure. NIHSS scores range from 0 to 42, with higher scores indicating more severe neurological deficits. The analysis was not powered, and had no pre-specified correction for multiple comparisons for a definitive analysis of subgroups. NIHSS, National Institutes of Health Stroke Scale; RD, risk difference; CI, confidence interval.
jos-2024-02250f4.tif
Table 1.
Baseline characteristics of patients included in the analysis
0-24 h group
24-48 h group
P
Total patients (n=1,757) Clopidogrel plus aspirin (n=902) Aspirin alone (n=855) P Total patients (n=1,158) Clopidogrel plus aspirin (n=600) Aspirin alone (n=558) P
Age (yr) 66 (59–74) 66 (59–73) 67 (59–74) 0.29 65 (58–73) 66 (58–72) 65 (58–74) 0.63 <0.01
Sex 0.73 0.34 0.08
 Male 1,164 (66.2) 601 (66.6) 563 (65.8) 731 (63.1) 371 (61.8) 360 (64.5)
 Female 593 (33.8) 301 (33.4) 292 (34.2) 427 (36.9) 229 (38.2) 198 (35.5)
Current smoking 632/1,745 (36.2) 335/895 (37.4) 297/850 (34.9) 0.28 335/1,147 (29.2) 168/594 (28.3) 167/553 (30.2) 0.48 <0.01
Current drinking* 386/1,743 (22.1) 203/893 (22.7) 183/850 (21.5) 0.55 204/1,148 (17.8) 98/596 (16.4) 106/552 (19.2) 0.22 <0.01
Comorbidities
 Hypertension 1,070 (60.9) 539 (59.8) 531 (62.1) 0.31 740 (63.9) 392 (65.3) 348 (62.4) 0.29 0.10
 Diabetes 454 (25.8) 250 (27.7) 204 (23.9) 0.07 288 (24.9) 151 (25.2) 137 (24.6) 0.81 0.56
 Previous stroke 546/1,747 (31.3) 275/894 (30.8) 271/853 (31.8) 0.65 393/1,153 (34.1) 207/597 (34.7) 186/556 (33.5) 0.66 0.11
 Previous TIA 9/1,741 (0.5) 7/895 (0.8) 2/846 (0.2) 0.11 3/1,153 (0.3) 0/598 (0.0) 3/555 (0.5) 0.07 0.29
Blood pressure at randomization
 Systolic (mm Hg) 153 (140–170) 153 (140–170) 153 (140–170) 0.99 150 (140–167) 150 (140–169) 151 (140–165) 0.69 0.26
 Diastolic (mm Hg) 90 (80–98) 90 (80–98) 90 (80–98) 0.30 90 (80–100) 90 (80–100) 90 (80–98) 0.22 0.67
Blood glucose (mmol/L) 6.0 (5.2–7.9) 6.1 (5.3–8.0) 6.0 (5.2–7.8) 0.25 6.0 (5.2–8.1) 6.0 (5.3–8.0) 6.1 (5.1–8.2) 0.57 0.92
Baseline NIHSS score§ 5 (4–6) 5 (4–6) 5 (4–6) 0.69 4 (4–6) 4 (4–6) 4 (4–6) 0.56 <0.01
Estimated premorbid function (mRS)ǁ 0.24 0.98 0.90
 No symptoms 1,247 (71.0) 630 (69.8) 617 (72.2) 825 (71.2) 426 (71.0) 399 (71.5)
 Symptoms without disability 508 (28.9) 270 (29.9) 238 (27.8) 331 (28.6) 173 (28.8) 158 (28.3)
 Mild disability 2 (0.1) 2 (0.2) 0 (0.0) 2 (0.2) 1 (0.2) 1 (0.2)
OTT (h) 9.0 (5.4–14.5) 8.8 (5.2–14.1) 9.0 (5.7–14.7) 0.37 28.6 (25.1–41.2) 28.1 (25.1–40.0) 29.0 (25.1–42.3) 0.26 <0.01
Presumed stroke cause 0.54 0.48 0.02
 UDC 1,032/1,752 (58.9) 523/899 (58.2) 509/853 (59.7) 740 (63.9) 394 (65.7) 346 (62.0)
 SAO 577/1,752 (32.9) 293/899 (32.6) 284/853 (33.3) 321 (27.7) 161 (26.8) 160 (28.7)
 LAA** 133/1,752 (7.6) 77/899 (8.6) 56/853 (6.6) 92 (7.9) 42 (7.0) 50 (9.0)
 ODC 6/1,752 (0.3) 4/899 (0.4) 2/853 (0.2) 5 (0.4) 3 (0.5) 2 (0.4)
 CE 4/1,752 (0.2) 2/899 (0.2) 2/853 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Location of responsible vessel (identified by circulation infarction) 0.22 0.11 <0.01
 Anterior 1,102/1,502 (73.4) 569/791 (71.9) 533/711 (75.0) 678/1,005 (67.5) 341/526 (64.8) 337/479 (70.4)
 Posterior 354/1,502 (23.6) 200/791 (25.3) 154/711 (21.7) 297/1,005 (29.6) 171/526 (32.5) 126/479 (26.3)
 Anterior & posterior 46/1,502 (3.1) 22/791 (2.8) 24/711 (3.4) 30/1,005 (3.0) 14/526 (2.7) 16/479 (3.3)

The data are shown with median (IQR) for continuous characteristic or frequency (percentages) for categorical characteristic.

TIA, transient ischemic attack; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; OTT, time from stroke onset to antiplatelet therapy; UDC, undetermined cause; SAO, small artery occlusion; LAA, large artery atherosclerosis; ODC, other determined cause; CE, cardioembolic; IQR, interquartile range.

* Current drinking means consuming alcohol at least once a week within 1 year before onset of the disease and consuming alcohol continuously for more than 1 year;

The comorbidities were based on the patient or family report;

Previous ischemic stroke referred only to the patients with prestroke mRS ≤1;

§ Patients with NIHSS scores of 6 to 16 were eligible for this study; NIHSS scores range from 0 to 42, with higher scores indicating more severe neurologic deficit;

ǁ Scores on the mRS of functional disability range from 0 (no symptoms) to 6 (death). No symptoms indicates scoring 0, symptoms without disability indicates scoring 1, and mild disability indicates scoring 2;

The presumed stroke cause was classified according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification system13 using clinical findings, brain imaging, and laboratory tests. Other determined causes included pulmonary embolism, peripheral vessel incident, and cardiovascular incident;

** The proportion of large vessel occlusion was balanced between clopidogrel plus aspirin and aspirin groups regardless of time from stroke onset to antiplatelet therapy.

Table 2.
Association between the continuous time from symptom onset with antiplatelet therapy with outcomes
Clopidogrel plus aspirin (n=1,502) Aspirin alone (n=1,413) Treatment effect metric Model 1*
Model 2
Model 3
Pint
Treatment difference (95% CI) P Treatment difference (95% CI) P Treatment difference (95% CI) P
Primary outcome
 END at 7 days§ 72/1,502 (4.8) 95/1,413 (6.7) RDǁ -1.9 (-3.6 to -0.2) 0.03 -1.9 (-3.1 to -0.7) <0.01 -1.9 (-3.6 to -0.2) 0.03 0.13
Secondary outcomes
 mRS 0–1 at 90 days 1,130/1,470 (76.9) 1,015/1,361 (74.6) RDǁ 2.4 (-0.8 to 5.6) 0.14 2.3 (0.0 to 4.5) 0.05 2.4 (-0.8 to 5.5) 0.14 0.92
 mRS at 90 days NA NA OR** 1.10 (0.96 to 1.25) 0.19 1.09 (0.99 to 1.20) 0.08 1.10 (0.97 to 1.26) 0.10 0.66
 Change in NIHSS at 14 days†† -0.56 (-0.99 to -0.22) -0.51 (-1.10 to -0.22) GMRǁ 0.00 (-0.05 to 0.04) 0.87 0.00 (-0.04 to 0.03) 0.81 0.00 (-0.05 to 0.04) 0.89 0.67
 New stroke within 90 days‡‡ 12/1,470 (0.8) 13/1,361 (1.0) HR§§ 0.86 (0.39 to 1.87) 0.70 0.86 (0.39 to 1.89) 0.71 0.84 (0.39 to 1.85) 0.67 0.28
 Other vascular events or death within 90 daysǁǁ 16/1,470 (1.1) 12/1,361 (0.9) HR§§ 1.24 (0.59 to 2.61) 0.58 1.20 (0.57 to 2.54) 0.63 1.24 (0.59 to 2.63) 0.59 0.13
Safety outcomes¶¶
 Any bleeding events 10/1,521 (0.7) 14/1,442 (1.0) RDǁ -0.3 (-1.0 to 0.3) 0.35 -0.3 (-1.0 to 0.3) 0.33 -0.3 (-1.0 to 0.3) 0.34 0.06
 Intracranial hemorrhage 1/1,521 (0.1) 2/1,442 (0.1) RDǁ -0.1 (-0.3 to 0.2) 0.54 -0.1 (-0.2 to 0.1) 0.38 -0.1 (-0.3 to 0.2) 0.55 0.89

The data are shown with median (IQR) for continuous characteristic or frequency (percentages) for categorical characteristic unless otherwise indicated.

CI, confidence interval; END, early neurological deterioration; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; RD, risk difference; OR, odds ratio; GMR, geometric mean ratio; HR, hazard ratio; IQR, interquartile range; NA, not applicable; TOAST, Trial of Org 10172 in Acute Stroke Treatment.

* Unadjusted analysis in the model;

Adjusted for time from symptom onset to antiplatelet therapy in the model;

Adjusted for time from symptom onset to antiplatelet therapy and pre-specified covariates (age, sex, history of diabetes, history of hypertension, NIHSS score at randomization, and presumed stroke cause based on the TOAST classification13);

§ END was defined as an increase between baseline and 7 days of ≥2 on the NIHSS score, but not as result of cerebral hemorrhage10;

ǁ Calculated using the generalized liner model;

Scores on the mRS of functional disability range from 0 (no symptoms) to 6 (death);

** A shift measures of function according to the full range of scores on the mRS at 90 days was analyzed by ordinal logistic regression, and the chi-square for the likelihood ratio test were 7.34 (P=0.20) in the model 1, 14.89 (P=0.11) in the model 2, and 12.20 (P=0.27) in the model 3;

†† Patients with NIHSS scores of 4 to 10 were eligible for this study; NIHSS scores range from 0 to 42, with higher scores indicating more severe neurologic deficit. The log(NIHSS+1) was analyzed using generalized linear model;

‡‡ New stroke included ischemic stroke and hemorrhagic stroke;

§§ Calculated using the Cox regression model;

ǁǁ Other vascular events included pulmonary embolism, peripheral vascular, or cardiovascular event;

¶¶ The safety outcomes were analyzed based on the safety analysis set of the ATAMIS trial.

Table 3.
Association between the categorical time from symptom onset with the start antiplatelet therapy with outcomes
Time (h) Clopidogrel plus aspirin (n=1,502) Aspirin alone (n=1,413) Treatment effect metric Model 1*
Model 4
Model 5
Pint
Treatment difference (95% CI) P Treatment difference (95% CI) P Treatment difference (95% CI) P
Primary outcome
 END at 7 days§ 0–24 51/902 (5.7) 79/855 (9.2) RDǁ -3.6 (-6.0 to -1.1) <0.01 -3.5 (-6.0 to -1.1) <0.01 -3.7 (-5.5 to -2.0) <0.01 0.03
24–48 21/600 (3.5) 16/558 (2.9) 0.6 (-1.4 to 2.7) 0.54 0.6 (-0.8 to 2.1) 0.39 0.6 (-0.8 to 2.0) 0.40
Secondary outcomes
 mRS 0–1 at 90 days 0–24 643/879 (73.2) 585/819 (71.4) RDǁ 1.7 (-2.5 to 6.0) 0.43 1.7 (-2.6 to 6.0) 0.44 1.8 (-1.2 to 4.8) 0.23 0.98
24–48 487/591 (82.4) 430/542 (79.3) 3.1 (-1.5 to 7.7) 0.19 3.1 (-0.2 to 6.3) 0.06 3.0 (-0.3 to 6.2) 0.07
 mRS at 90 days 0–24 NA NA OR** 1.10 (0.93 to 1.31) 0.27 1.10 (0.93 to 1.31) 0.27 1.11 (0.98 to 1.25) 0.10 0.25
24–48 NA NA 1.06 (0.86 to 1.32) 0.59 1.06 (0.91 to 1.24) 0.45 1.06 (0.91 to 1.23) 0.50
 Change in NIHSS at 14 day†† 0–24 -0.51 (-0.91 to -0.22) -0.51 (-0.98 to -0.22) GMRǁ 0.01 (-0.05 to 0.07) 0.66 0.02 (-0.04 to 0.08) 0.60 0.02 (-0.03 to 0.06) 0.43 0.20
24–48 -0.56 (-1.10 to -0.25) -0.69 (-1.10 to -0.34) -0.03 (-0.10 to 0.04) 0.37 -0.03 (-0.08 to 0.02) 0.19 -0.04 (-0.08 to 0.01) 0.17
 New stroke within 90 days‡‡ 0–24 5/879 (0.6) 9/819 (1.1) HR§§ 0.52 (0.17 to 1.54) 0.24 0.52 (0.17 to 1.56) 0.24 0.54 (0.18 to 1.61) 0.27 0.12
24–48 7/591 (1.2) 4/542 (0.7) 1.61 (0.47 to 5.50) 0.45 1.61 (0.47 to 5.49) 0.45 1.84 (0.53 to 6.39) 0.34
 Other vascular events or death within 90 daysǁǁ 0–24 13/879 (1.5) 11/819 (1.3) HR§§ 1.10 (0.49 to 2.46) 0.81 1.12 (0.50 to 2.51) 0.78 1.17 (0.52 to 2.63) 0.71 0.37
24–48 3/591 (0.5) 1/542 (0.2) 2.76 (0.29 to 26.49) 0.38 2.75 (0.29 to 26.44) 0.38 2.35 (0.21 to 26.85) 0.49
Safety outcomes¶¶
 Any bleeding events 0–24 4/914 (0.4) 11/873 (1.3) RDǁ -0.8 (-1.7 to 0.0) 0.06 -0.8 (-1.7 to 0.0) 0.05 -0.9 (-1.5 to -0.3) <0.01 0.05
24–48 6/607 (1.0) 3/569 (0.5) 0.5 (-0.5 to 1.5) 0.36 0.5 (-0.2 to 1.2) 0.20 0.5 (-0.2 to 1.2) 0.20
 Intracranial hemorrhage 0–24 1/914 (0.1) 2/873 (0.2) RDǁ -0.1 (-0.5 to 0.3) 0.54 -0.1 (-0.7 to 0.6) 0.93 -0.1 (-0.4 to 0.2) 0.39 0.99
24–48 0/607 (0.0) 0/569 (0.0) NA NA NA NA NA NA

The data are shown with median (IQR) for continuous characteristic or frequency (percentages) for categorical characteristic unless otherwise indicated.

CI, confidence interval; END, early neurological deterioration; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; RD, risk difference; OR, odds ratio; GMR, geometric mean ratio; HR, hazard ratio; IQR, interquartile range; NA, not applicable; TOAST, Trial of Org 10172 in Acute Stroke Treatment.

* Unadjusted analysis in the model;

Adjusted for unbalanced covariates between clopidogrel plus aspirin group and aspirin alone group;

Adjusted for pre-specified covariates (age, sex, history of diabetes, history of hypertension, NIHSS score at randomization, and presumed stroke cause based on the TOAST classification13) and unbalanced covariates between clopidogrel plus aspirin group and aspirin alone group;

§ END was defined as an increase between baseline and 7 days of ≥2 on the NIHSS score, but not as result of cerebral hemorrhage10;

ǁ Calculated using the generalized liner model;

Scores on the mRS of functional disability range from 0 (no symptoms) to 6 (death);

** A shift measures of function according to the full range of scores on the mRS at 90 days was analyzed by ordinal logistic regression, and the chi-square for the likelihood ratio test were 3.22 (P=0.67) and 6.71 (P=0.24) in the model 1, 7.03 (P=0.72) and 8.47 (P=0.58) in the model 4, and 48.77 (P=0.16) and 13.27 (P=0.21) in the model 5;

†† Patients with NIHSS scores of 4 to 10 were eligible for this study; NIHSS scores range from 0 to 42, with higher scores indicating more severe neurologic deficit. The log(NIHSS+1) was analyzed using generalized linear model;

‡‡ New stroke included ischemic stroke and hemorrhagic stroke;

§§ Calculated using the Cox regression model;

ǁǁ Other vascular events included pulmonary embolism, peripheral vascular, or cardiovascular event;

¶¶ The safety outcomes were analyzed based on the safety analysis set of the ATAMIS trial.

Appendix

Appendix 1. STROBE Statement—checklist of items that should be included in reports of observational studies

jos-2024-02250-Appendix-1.pdf
TOOLS
Similar articles